Conference Coverage

Refining SLE cardiovascular risk estimation


 

AT ACC 2017

– Red blood cell distribution width provides a novel tool for cardiovascular risk stratification in patients with systemic lupus erythematosus (SLE), Chang H. Kim, MD, reported at the annual meeting of the American College of Cardiology.

In a retrospective cohort study of nearly 70,000 patients with SLE, the 10-year rate of major adverse cardiovascular events (MACE) rose stepwise according to quintile of red cell distribution width (RDW) from 5.3% in patients with an RDW of 13.2% or less to 38.6% in those with an RDW of 15.8% or greater, according to Dr. Kim of Case Western Reserve University in Cleveland.

He utilized the Explorys database to determine the 10-year cumulative incidence of MACE – defined as acute MI, heart failure, or cerebrovascular accident – during 2007-2016 in 69,920 patients with SLE and 14,825,240 controls. Explorys is an 8-year-old Cleveland-based company that maintains a health care database incorporating 26 health care systems across the United States with nearly 50 million patients. It is part of IBM Watson Health.

10-year cumulative incidence of major cardiovascular events in SLE

The MACE rate in patients with SLE displayed a graded increase in association with RDW quintile as measured in a routine CBC. (See table.) MACE rates were significantly higher in male than female SLE patients, but the graded relationship between RDW quintile and 10-year incidence of MACE persisted after adjustment for gender and the presence of anemia.

A graded association between RDW quintile and MACE also was noted in the control group of nearly 15 million individuals, but the absolute incidence of MACE in the non-SLE controls was far lower.

Dr. Kim reported having no financial conflicts regarding this unfunded study.

Recommended Reading

Disease activity, not lipid levels, appear to affect CV risk with tocilizumab
MDedge Rheumatology
Chronic inflammatory disease patients at greater risk of major CV events
MDedge Rheumatology
Gout increases risk of vascular disease, especially for women
MDedge Rheumatology
FDA will strengthen heart attack, stroke risk warnings for all NSAIDs
MDedge Rheumatology
Heart attack risk rises in first month after knee, hip arthroplasty
MDedge Rheumatology
ESC: Celecoxib safety study may soothe cardio concerns
MDedge Rheumatology
Greater myocardial inflammation found in RA patients after heart attack
MDedge Rheumatology
VIDEO: PRECISION exonerates celecoxib: cardiovascular risk is no worse than that of nonselective NSAIDs
MDedge Rheumatology
VIDEO: Celecoxib just as safe as naproxen or ibuprofen in OA and RA
MDedge Rheumatology
No rise in CV events seen with tocilizumab
MDedge Rheumatology